Skip to main content

Table 1 Clinical characteristics for each group study

From: No detectable differential microRNA expression between non-atherosclerotic arteries of type 2 diabetic patients (treated or untreated with metformin) and non-diabetic patients

 

Study group 1 (explorative analysis)

T2DM

n = 18

Non-DM

n = 30

P

T2DM (− Met)

n = 8

Non-DM

n = 30

P

T2DM (+ Met)

n = 10

T2DM (− Met)

n = 8

P

Mean ± SD

Mean ± SD

Mean ± SD

Mean ± SD

Mean ± SD

Mean ± SD

Age at surgery, years

66.61 ± 7.51

63.60 ± 8.98

0.219

67.13 ± 8.63

63.60 ± 8.98

0.330

66.20 ± 6.94

67.13 ± 8.63

0.809

HbA1c, %

6.94 ± 1.21

5.74 ± 0.38

0.002

7.37 ± 1.52

5.74 ± 0.38

0.029

6.56 ± 0.76

7.37 ± 1.52

0.236

HbA1c, mmol/mol

52.28 ± 13.07

39.21 ± 4.08

0.002

56.93 ± 16.41

39.21 ± 4.08

0.029

48.21 ± 8.36

56.93 ± 16.41

0.238

Cholesterol, mmol/L

4.19 ± 1.11

4.45 ± 1.16

0.486

4.27 ± 1.16

4.45 ± 1.16

0.721

4.11 ± 1.14

4.27 ± 1.16

0.803

LDL, mmol/L

2.31 ± 0.70

2.61 ± 1.01

0.267

2.41 ± 0.76

2.61 ± 1.01

0.571

2.21 ± 0.68

2.41 ± 0.76

0.614

HDL, mmol/L

1.16 ± 0.38

1.21 ± 0.33

0.684

1.01 ± 0.24

1.21 ± 0.33

0.101

1.30 ± 0.46

1.01 ± 0.24

0.168

Triglycerides, mmol/L

1.88 ± 1.21

1.45 ± 0.63

0.210

2.23 ± 1.54

1.45 ± 0.63

0.234

1.58 ± 0.81

2.23 ± 1.54

0.344

Creatinine, µmol/L

83.72 ± 15.42

85.70 ± 13.14

0.653

76.88 ± 11.22

85.70 ± 13.14

0.080

89.20 ± 16.62

76.88 ± 11.22

0.080

BMI, kg/m2

29.98 ± 3.06

27.26 ± 3.77

0.010

29.24 ± 2.57

27.26 ± 3.77

0.104

30.57 ± 3.42

29.24 ± 2.57

0.360

SBP, mm Hg

134.22 ± 19.47

138.42 ± 22.13

0.510

141.38 ± 22.36

138.42 ± 22.13

0.749

128.50 ± 15.66

141.38 ± 22.36

0.192

DBP, mm Hg

75.06 ± 11.61

77.70 ± 12.78

0.476

80.00 ± 14.63

77.70 ± 12.78

0.697

71.10 ± 7.02

80.00 ± 14.63

0.146

Male sex, %

100

100

100

100

100

100

Statins, n

18

30

8

30

10

8

Antihypertensives, n

17

26

0.637

7

26

1.000

10

7

0.444

Insulins, n

6

0

0.002

4

0

< 0.001

2

4

0.321

Oral antidiabetic agents, n

12

0

< 0.001

2

0

0.040

10

2

0.002

 

Study group 2 (targeted analysis)

T2DM

n = 26

Non-DM

n = 26

P

T2DM (− Met)

n = 11

Non-DM

n = 26

P

T2DM (+ Met)

n = 15

T2DM (− Met)

n = 11

P

Mean ± SD

Mean ± SD

Mean ± SD

Mean ± SD

Mean ± SD

Mean ± SD

Age at surgery, years

67.84 ± 4.83

68.99 ± 5.24

0.410

67.35 ± 4.21

68.99 ± 5.24

0.367

68.25 ± 5.35

67.35 ± 4.21

0.670

HbA1c, %

7.11 ± 1.11

5.60 ± 0.37

< 0.001

7.41 ± 1.39

5.60 ± 0.37

< 0.001

6.84 ± 0.75

7.41 ± 1.39

0.231

HbA1c, mmol/mol

54.24 ± 12.17

37.71 ± 4.03

< 0.001

57.48 ± 15.19

37.71 ± 4.03

< 0.001

51.28 ± 8.16

57.48 ± 15.19

0.230

Cholesterol, mmol/L

3.76 ± 1.04

4.20 ± 1.26

0.230

4.00 ± 1.32

4.20 ± 1.26

0.692

3.55 ± 0.68

4.00 ± 1.32

0.329

LDL, mmol/L

1.85 ± 0.69

2.33 ± 0.90

0.058

2.07 ± 0.87

2.33 ± 0.90

0.447

1.65 ± 0.42

2.07 ± 0.87

0.174

HDL, mmol/L

1.13 ± 0.24

1.41 ± 0.51

0.030

1.14 ± 0.25

1.41 ± 0.51

0.129

1.12 ± 0.25

1.14 ± 0.25

0.851

Triglycerides, mmol/L

1.90 ± 0.89

1.21 ± 0.35

0.002

1.89 ± 1.03

1.21 ± 0.35

0.011

1.91 ± 0.79

1.89 ± 1.03

0.960

Creatinine, µmol/L

96.12 ± 29.47

86.40 ± 16.93

0.160

95.64 ± 32.61

86.40 ± 16.93

0.269

96.47 ± 28.12

95.64 ± 32.61

0.945

BMI, kg/m2

28.66 ± 3.95

27.13 ± 3.69

0.150

27.21 ± 3.41

27.13 ± 3.69

0.949

29.73 ± 4.08

27.21 ± 3.41

0.110

SBP, mm Hg

141.12 ± 18.64

139.92 ± 19.79

0.820

138.82 ± 10.59

139.92 ± 19.79

0.863

142.80 ± 23.09

138.82 ± 10.59

0.601

DBP, mm Hg

74.92 ± 10.42

77.73 ± 10.71

0.340

75.73 ± 12.28

77.73 ± 10.71

0.621

74.33 ± 9.24

75.73 ± 12.28

0.744

Male sex, %

85

85

82

85

87

82

Statins, n

26

26

11

26

15

11

Antihypertensives, n

21

13

0.040

8

13

0.285

13

8

0.620

Insulins, n

6

0

0.023

3

0

0.021

3

3

0.218

Oral antidiabetic agents, n

19

0

< 0.001

4

0

0.005

15

4

< 0.001

  1. For each study group three comparisons of clinical data are made: T2DM vs. non-DM patients; non-metformin-treated T2DM (− Met) vs. non-DM patients; and non-metformin-treated T2DM (− Met) vs. metformin-treated T2DM patients (+ Met). Results are shown as mean ± SD, percentage (%) or number (n) as indicated
  2. In study group 1, one slide cracked during the hybridization process. Since no miRNA expression data is available for this sample, the accompanying patient data is not included in the table
  3. HbA1c glycated hemoglobin, LDL low-density lipoprotein, HDL high-density lipoprotein, BMI Body-mass index, SBP systolic blood pressure, DBP diastolic blood pressure